Summary by Moomoo AI
Aurora Cannabis and Vectura Fertin Pharma announced a commercial collaboration on August 1, 2024. The partnership will initially launch Cogent International's new CBD lozenge on Aurora's Canadian medical cannabis patient platform. This collaboration aims to gather patient feedback and build real-world data for future analysis.Following a successful launch, the companies may explore opportunities to commercialize other Vectura Fertin Pharma medical cannabis products in Canada. The agreement has an initial term of 24 months, with the first SKU targeted for launch later in 2024. Cogent will manufacture, package, and label the products for sale and distribution through Aurora's e-commerce channel.This partnership leverages Aurora's leading patient platform in Canada to support advancements in medical cannabis and provide patients access to new products. It also demonstrates increased interest in medical cannabis as a healthcare option for Canadians, aligning with both companies' focus on improving people's lives through scientific innovation and high-quality products.
